Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Assets Average (2021 - 2025)

Aligos Therapeutics' Assets Average history spans 5 years, with the latest figure at $99.1 million for Q4 2025.

  • For Q4 2025, Assets Average rose 25.09% year-over-year to $99.1 million; the TTM value through Dec 2025 reached $99.1 million, up 25.09%, while the annual FY2025 figure was $79.3 million, 28.42% down from the prior year.
  • Assets Average reached $99.1 million in Q4 2025 per ALGS's latest filing, down from $122.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $249.2 million in Q4 2021 to a low of $79.3 million in Q4 2024.
  • Average Assets Average over 5 years is $149.0 million, with a median of $134.2 million recorded in 2023.
  • Peak YoY movement for Assets Average: plummeted 44.61% in 2023, then grew 25.09% in 2025.
  • A 5-year view of Assets Average shows it stood at $249.2 million in 2021, then crashed by 37.65% to $155.4 million in 2022, then dropped by 23.61% to $118.7 million in 2023, then tumbled by 33.22% to $79.3 million in 2024, then rose by 25.09% to $99.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Assets Average are $99.1 million (Q4 2025), $122.2 million (Q3 2025), and $142.7 million (Q2 2025).